Columbia Care, LLC announced that it has entered into a licensing agreement with Rhinomed for the collaborative development of nasally-delivered cannabis-based medicines. Columbia Care has exclusive rights to develop, import, market, promote, distribute and sell the developed products in the United States. Under the terms of the agreement, Columbia Care and Rhinomed will collaborate on the development of one or more new versions of Rhinomed's existing device.

The program, which will be developed in Columbia Care's research and manufacturing facilities nationally, will optimize delivery of consistent doses of Columbia Care's pharmaceutical-quality cannabis-based medicines via nasal administration.